Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]
News [4946]
Articles [204]
Editorials [8]
Conferences [138]
elearning [14]
Super-enhancer analysis reveals subtypes in AML and MDS
Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA
Super-enhancer analysis reveals subtypes in AML and MDS ( Dr Michael McKeown - Syros Pharmaceuticals, Cambridge, USA )
12 Jun 2016
Better screening programmes needed for haematological malignancies such as...
Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany
Better screening programmes needed for haematological malignancies such as leukaemia ( Dr Brigitte Schlegerberger - Hannover Medical School, Hannover, Germany )
12 Jun 2016
Novel therapies for older patients with AML and MDS
Prof Naval Daver - MD Anderson Cancer Center, Houston, United States
Novel therapies for older patients with AML and MDS ( Prof Naval Daver - MD Anderson Cancer Center, Houston, United States )
12 Jun 2016
Karyotyping a CLL subset with ibrutinib susceptibility
Dr Jeffrey Jones - Ohio State University, Columbus, USA
Karyotyping a CLL subset with ibrutinib susceptibility ( Dr Jeffrey Jones - Ohio State University, Columbus, USA )
12 Jun 2016
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML
Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML ( Dr Vincent-Philippe Lavallée - Université de Montréal, Montréal, Canada )
12 Jun 2016
Targeted genome editing in haematopoeitic stem cells
Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy
Targeted genome editing in haematopoeitic stem cells ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )
11 Jun 2016
A microRNA driver of B-cell leukaemia
Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy
A microRNA driver of B-cell leukaemia ( Prof Luigi Naldini - Universita Vita-Salute San Raffaele, Milan, Italy )
11 Jun 2016
Risk adapted therapy for acute myeloid leukaemia
Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain
Risk adapted therapy for acute myeloid leukaemia ( Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain )
11 Jun 2016
Evaluation of ibrutinib in treatment of CLL with 17p deletion
Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA
Evaluation of ibrutinib in treatment of CLL with 17p deletion ( Dr Jeffrey Jones - OSU James Cancer Hospital, Columbus, USA )
10 Jun 2016
An overview of MCL from EHA 2016
Professor Simon Rule and Professor Steven Le Gouill
An overview of MCL from EHA 2016 ( Professor Simon Rule and Professor Steven Le Gouill )
10 Jun 2016
The value and strategy for incorporating biosimilars Into clinical practice
Dr Francisco Esteva - New York University, New York, USA
The value and strategy for incorporating biosimilars Into clinical practice ( Dr Francisco Esteva - New York University, New York, USA )
7 Jun 2016
Checkpoint inhibitor therapy benefits advanced bladder cancer patients
Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA
Checkpoint inhibitor therapy benefits advanced bladder cancer patients ( Dr Arjun Vasant Balar - NYU Langone Medical Center, New York, USA )
7 Jun 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation